vs
Amneal Pharmaceuticals, Inc.（AMRX）与Ryman Hospitality Properties, Inc.（RHP）财务数据对比。点击上方公司名可切换其他公司
Ryman Hospitality Properties, Inc.的季度营收约是Amneal Pharmaceuticals, Inc.的1.0倍（$737.8M vs $722.5M），Amneal Pharmaceuticals, Inc.净利率更高（10.8% vs 10.1%，领先0.7%），Ryman Hospitality Properties, Inc.同比增速更快（13.9% vs 3.9%），过去两年Ryman Hospitality Properties, Inc.的营收复合增速更高（18.2% vs 1.5%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
莱曼酒店地产是一家主营酒店、度假村、娱乐及媒体业务的企业，得名于旗下位于田纳西州纳什维尔的国家历史地标莱曼礼堂。公司历史可追溯至曾为俄克拉荷马出版公司子公司时期，1983年收购WSM公司后奠定现代业务基础，同时将知名演出IP大奥普里等核心资产纳入麾下。
AMRX vs RHP — 直观对比
营收规模更大
RHP
是对方的1.0倍
$722.5M
营收增速更快
RHP
高出10.0%
3.9%
净利率更高
AMRX
高出0.7%
10.1%
两年增速更快
RHP
近两年复合增速
1.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $722.5M | $737.8M |
| 净利润 | $78.0M | $74.5M |
| 毛利率 | 44.3% | 41.4% |
| 营业利润率 | — | 19.4% |
| 净利率 | 10.8% | 10.1% |
| 营收同比 | 3.9% | 13.9% |
| 净利润同比 | 217.0% | 3.0% |
| 每股收益（稀释后） | $0.19 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRHP
| Q1 26 | $722.5M | — | ||
| Q4 25 | $814.3M | $737.8M | ||
| Q3 25 | $784.5M | $592.5M | ||
| Q2 25 | $724.5M | $659.5M | ||
| Q1 25 | $695.4M | $587.3M | ||
| Q4 24 | $730.5M | $647.6M | ||
| Q3 24 | $702.5M | $550.0M | ||
| Q2 24 | $701.8M | $613.3M |
净利润AMRXRHP
| Q1 26 | $78.0M | — | ||
| Q4 25 | $35.1M | $74.5M | ||
| Q3 25 | $2.4M | $34.9M | ||
| Q2 25 | $22.4M | $71.8M | ||
| Q1 25 | $12.2M | $63.0M | ||
| Q4 24 | $-31.1M | $72.3M | ||
| Q3 24 | $-156.0K | $59.0M | ||
| Q2 24 | $6.0M | $100.8M |
毛利率AMRXRHP
| Q1 26 | 44.3% | — | ||
| Q4 25 | 36.5% | 41.4% | ||
| Q3 25 | 34.9% | 40.9% | ||
| Q2 25 | 39.5% | 49.7% | ||
| Q1 25 | 36.8% | 44.4% | ||
| Q4 24 | 36.0% | 40.4% | ||
| Q3 24 | 38.4% | 43.1% | ||
| Q2 24 | 35.6% | 48.4% |
营业利润率AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | 13.8% | 19.4% | ||
| Q3 25 | 9.0% | 15.0% | ||
| Q2 25 | 15.4% | 21.1% | ||
| Q1 25 | 14.4% | 19.8% | ||
| Q4 24 | 10.4% | 18.6% | ||
| Q3 24 | 12.6% | 19.3% | ||
| Q2 24 | 13.6% | 27.4% |
净利率AMRXRHP
| Q1 26 | 10.8% | — | ||
| Q4 25 | 4.3% | 10.1% | ||
| Q3 25 | 0.3% | 5.9% | ||
| Q2 25 | 3.1% | 10.9% | ||
| Q1 25 | 1.8% | 10.7% | ||
| Q4 24 | -4.3% | 11.2% | ||
| Q3 24 | -0.0% | 10.7% | ||
| Q2 24 | 0.9% | 16.4% |
每股收益（稀释后）AMRXRHP
| Q1 26 | $0.19 | — | ||
| Q4 25 | $0.10 | $1.12 | ||
| Q3 25 | $0.01 | $0.53 | ||
| Q2 25 | $0.07 | $1.12 | ||
| Q1 25 | $0.04 | $1.00 | ||
| Q4 24 | $-0.10 | $1.12 | ||
| Q3 24 | $0.00 | $0.94 | ||
| Q2 24 | $0.02 | $1.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $471.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $750.2M |
| 总资产 | — | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | $471.4M | ||
| Q3 25 | $201.2M | $483.3M | ||
| Q2 25 | $71.5M | $420.6M | ||
| Q1 25 | $59.2M | $413.9M | ||
| Q4 24 | $110.6M | $477.7M | ||
| Q3 24 | $74.0M | $534.9M | ||
| Q2 24 | $43.8M | $498.4M |
总债务AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | $-70.8M | $750.2M | ||
| Q3 25 | $-109.5M | $758.5M | ||
| Q2 25 | $-112.1M | $800.4M | ||
| Q1 25 | $-131.7M | $531.5M | ||
| Q4 24 | $-109.3M | $549.0M | ||
| Q3 24 | $-93.4M | $551.9M | ||
| Q2 24 | $-57.5M | $562.6M |
总资产AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | $3.7B | $6.2B | ||
| Q3 25 | $3.6B | $6.2B | ||
| Q2 25 | $3.4B | $6.1B | ||
| Q1 25 | $3.4B | $5.2B | ||
| Q4 24 | $3.5B | $5.2B | ||
| Q3 24 | $3.5B | $5.2B | ||
| Q2 24 | $3.5B | $5.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $164.7M |
| 自由现金流经营现金流 - 资本支出 | — | $58.5M |
| 自由现金流率自由现金流/营收 | — | 7.9% |
| 资本支出强度资本支出/营收 | — | 14.4% |
| 现金转化率经营现金流/净利润 | — | 2.21× |
| 过去12个月自由现金流最近4个季度 | — | $232.4M |
8季度趋势，按日历期对齐
经营现金流AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $164.7M | ||
| Q3 25 | $118.5M | $205.2M | ||
| Q2 25 | $83.8M | $122.5M | ||
| Q1 25 | $7.4M | $98.2M | ||
| Q4 24 | $118.1M | $166.6M | ||
| Q3 24 | $141.8M | $218.1M | ||
| Q2 24 | $39.7M | $184.3M |
自由现金流AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | $108.5M | $58.5M | ||
| Q3 25 | $106.2M | $135.4M | ||
| Q2 25 | $61.0M | $53.0M | ||
| Q1 25 | $-5.8M | $-14.5M | ||
| Q4 24 | $102.9M | $76.0M | ||
| Q3 24 | $124.8M | $85.7M | ||
| Q2 24 | $29.0M | $78.8M |
自由现金流率AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | 13.3% | 7.9% | ||
| Q3 25 | 13.5% | 22.9% | ||
| Q2 25 | 8.4% | 8.0% | ||
| Q1 25 | -0.8% | -2.5% | ||
| Q4 24 | 14.1% | 11.7% | ||
| Q3 24 | 17.8% | 15.6% | ||
| Q2 24 | 4.1% | 12.9% |
资本支出强度AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | 14.4% | ||
| Q3 25 | 1.6% | 11.8% | ||
| Q2 25 | 3.2% | 10.5% | ||
| Q1 25 | 1.9% | 19.2% | ||
| Q4 24 | 2.1% | 14.0% | ||
| Q3 24 | 2.4% | 24.1% | ||
| Q2 24 | 1.5% | 17.2% |
现金转化率AMRXRHP
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 2.21× | ||
| Q3 25 | 50.00× | 5.88× | ||
| Q2 25 | 3.74× | 1.71× | ||
| Q1 25 | 0.61× | 1.56× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 3.70× | ||
| Q2 24 | 6.62× | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
RHP
| Hotel Other | $157.7M | 21% |
| Gaylord Opryland | $147.4M | 20% |
| Hotel Transient Rooms | $93.6M | 13% |
| Hotel Food And Beverage Outlets | $92.2M | 12% |
| Gaylord Palms | $88.2M | 12% |
| Jw Marriott Hill Country | $53.7M | 7% |
| Entertainment Admissions And Ticketing | $43.1M | 6% |
| Entertainment Food And Beverage | $38.1M | 5% |
| Entertainment Retail And Other | $28.3M | 4% |
| Ac Hotel | $2.4M | 0% |
